Technology
Cyto Pulse focuses on the most efficient delivery of DNA vaccines by using electric field pulses to directly uptake
DNA into immune-rich cells in the skin. The basis of this technology, commonly known as electroporation (EP),
has proven to have an enormous impact on enhancing immune system
response in comparison to naked injection into muscle as well as
ballistic particle delivery
by gene gun. Cyto Pulse has further optimized on standard
electroporation by discovering its own novel Pulse Agile® patented waveforms that produce high
levels of both neutralizing antibodies and killer T-cells.
Targeting
skin cells in particular provides Cyto Pulse with significant
advantages over other available intramuscular electroporation systems.
While skin contains an abudance of dendritic antigen presenting cells
and mesenchymal origin cells, both of which are critical to the initial
immune stimulation, these kinds of cells are otherwise sparse in muscle
tissue. The length of the electrode needles are also reduced which
allows for a significant improvement in patient comfort
considering skin has fewer nerve endings.
Two clinical vaccine delivery systems have been designed by Cyto Pulse
to meet the varying needs of patients worldwide: Derma Vax™
and Easy Vax™. In addition, Cyto Pulse internally develops DNA vaccine
therapeutics and in-licenses DNA vaccines through collaboration partners.
)
)